becon800 (99.73)

DYAX is the Ticket!

July 13, 2009 – Comments (1) | RELATED TICKERS: DYAX

I've had a buy on my picks for DYAX a month or so now and feel comfortable giving a full recommendation on the Blog. DYAX is one of the rare biotechs with revenue coming in from a patent line where other biotechs can screen their proteins for potential human benefits. Over 70 different companies have seen this benefit!

I'm not to the point where this is a major comfort zone. DYAX is in the red and will be there for some time. The big positives are these; 1) DYAX will continue to rise this year on an expected approval December 1st. The indication is small (Orphan Drug), but will provide some legitamacy for their company. 2)DYAX has signed a lisencing agreement with Cubist on the same molecule, for a different indication - a much larger one! The Phase II data will be out next year. 3) Other cantidates are being snatched up. Sanofi Aventis took on a DYAX cancer cantidate.

Since the current market cap is around 150M, DYAX has a great amount of room to grow, and I beleive it will not leave investors in the red for the future. In fact, DYAX is a long term hold if you ask me. 5, 10, or 15 years should provide significant increases for investors.

As with other recommendations, I am personally at risk myself for a reasonable sum. Current price is $3.23 at todays close. I got in at $2.06.

becon800